ESMO 2017 | Metastatic melanoma: the CheckMate 067 and 069 trials

Caroline Robert , MD, PhD, from the Gustave Roussy Cancer Institute, Villejuif, France, discusses her presentation at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. Dr Robert describes two recent studies in metastatic melanoma in her presentation, the CheckMate 067 trial, and the CheckMate 069 trial. The CheckMate 067 study (NCT01844505) is a randomised Phase III trial comparing the efficacy of nivolumab and ipilimumab. The CheckMate 069 study (NCT01927419) is a Phase II trial investigating the combination of nivolumab plus ipilumumab compared to ipilumumab alone.